1. Partin AW,
Kattan MW,
Subong EN,
et al.
Combination of prostate-specific antigen,
clinical stage,
and Gleason score to predict pathological stage of localized prostate cancer.
A multi-institutional update.
JAMA 1997;277:1445-51.
2. Partin AW,
Mangold LA,
Lamm DM,
Walsh PC,
Epstein JI,
Pearson JD.
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
Urology 2001;58:843-8.
3. Huch Boni RA,
Boner JA,
Debatin JF,
et al.
Optimization of prostate carcinoma staging: comparison of imaging and clinical methods.
Clin Radiol 1995;50:593-600.
4. Giusti S,
Caramella D,
Fruzzetti E,
Lazzereschi M,
Tognetti A,
Bartolozzi C.
Peripheral zone prostate cancer.
Pre-treatment evaluation with MR and 3D (1)H MR spectroscopic imaging: correlation with pathologic findings.
Abdom Imaging;35:757-63.
5. Ohori M,
Kattan MW,
Koh H,
et al.
Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer.
J Urol 2004;171:1844-9; discussion 9.
6. Epstein JI,
Partin AW,
Potter SR,
Walsh PC.
Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters.
Urology 2000;56:283-8.
7. Kattan MW,
Eastham JA,
Stapleton AM,
Wheeler TM,
Scardino PT.
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.
J Natl Cancer Inst 1998;90:766-71.
8. Morton G.
The best method for dose escalation: Prostate brachytherapy.
Can Urol Assoc J;6:196-8.
9. Sedelaar JP,
van Roermund JG,
van Leenders GL,
Hulsbergen-van de Kaa CA,
Wijkstra H,
de la Rosette JJ.
Three-dimensional grayscale ultrasound: evaluation of prostate cancer compared with benign prostatic hyperplasia.
Urology 2001;57:914-20.
10. Mohler JL,
Armstrong AJ,
Bahnson RR,
et al.
Prostate Cancer,
Version 3.2012 Featured Updates to the NCCN Guidelines.
J Natl Compr Canc Netw;10:1081-7.
11. D'Amico AV,
Whittington R,
Malkowicz SB,
et al.
Biochemical outcome after radical prostatectomy,
external beam radiation therapy,
or interstitial radiation therapy for clinically localized prostate cancer.
JAMA 1998;280:969-74.
12. Akin O,
Hricak H.
Imaging of prostate cancer.
Radiol Clin North Am 2007;45:207-22.
13. Wang L,
Hricak H,
Kattan MW,
Chen HN,
Scardino PT,
Kuroiwa K.
Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms.
Radiology 2006;238:597-603.
14. Jager GJ,
Ruijter ET,
van de Kaa CA,
et al.
Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology.
AJR Am J Roentgenol 1996;166:845-52.
15. McKenna DA,
Coakley FV,
Westphalen AC,
et al.
Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience.
Radiology 2008;247:141-6.
16. Engelbrecht MR,
Jager GJ,
Laheij RJ,
Verbeek AL,
van Lier HJ,
Barentsz JO.
Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis.
Eur Radiol 2002;12:2294-302.
17. Turkbey B,
Mani H,
Shah V,
et al.
Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds.
J Urol;186:1818-24.
18. Augustin H,
Fritz GA,
Ehammer T,
Auprich M,
Pummer K.
Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables.
Acta Radiol 2009;50:562-9.
19. Mullerad M,
Hricak H,
Wang L,
Chen HN,
Kattan MW,
Scardino PT.
Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging.
Radiology 2004;232:140-6.
20. Futterer JJ,
Engelbrecht MR,
Jager GJ,
et al.
Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils.
Local staging accuracy of prostate cancer using endorectal coil MR imaging.
Eur Radiol 2007;17:1055-65.
21. Park BK,
Kim B,
Kim CK,
Lee HM,
Kwon GY.
Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer.
J Comput Assist Tomogr 2007;31:534-8.
22. Kim B,
Breau RH,
Papadatos D,
et al.
Diagnostic accuracy of surface coil magnetic resonance imaging at 1.5 T for local staging of elevated risk prostate cancer.
Can Urol Assoc J;4:257-62.
23. Clarke DH,
Banks SJ,
Wiederhorn AR,
et al.
The role of endorectal coil MRI in patient selection and treatment planning for prostate seed implants.
Int J Radiat Oncol Biol Phys 2002;52:903-10.
24. Fuchsjager MH,
Pucar D,
Zelefsky MJ,
et al.
Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI.
Int J Radiat Oncol Biol Phys;78:743-50.
25. Joseph T,
McKenna DA,
Westphalen AC,
et al.
Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy.
Int J Radiat Oncol Biol Phys 2009;73:665-71.
26. Nguyen PL,
Whittington R,
Koo S,
et al.
Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer.
Int J Radiat Oncol Biol Phys 2004;59:400-5.
27. Riaz N,
Afaq A,
Akin O,
et al.
Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy.
Int J Radiat Oncol Biol Phys;84:707-11.